Indirect Comparison Between Eltrombopag & Romiplostim
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Thrombocytopaenia
Intervention: Eltrombopag (Drug); Romiplostim (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
An indirect comparison to compare the efficacy of eltrombopag versus romiplostim
Clinical Details
Official title: Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events
Study design: Time Perspective: Retrospective
Primary outcome: Durable response: platelet count of >=50 and <400 Gi/LOverall response: either a durable response or a transient platelet response
Detailed description:
An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and
romiplostim using placebo as a common comparator
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adults with ITP
- Pre-specified treatment
- Prospective clinical studies with at least 10 patients
Exclusion Criteria:
- Adults with ITP for other reasons
Locations and Contacts
Additional Information
Starting date: August 2009
Last updated: November 3, 2011
|